Barclays lowered the firm’s price target on Cytokinetics (CYTK) to $53 from $55 and keeps an Overweight rating on the shares following the Q1 report.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Receives Buy Rating Amid Positive Outlook for Aficamten and Strong Financial Position
- Cytokinetics’ Earnings Call: Balancing Progress and Challenges
- Cytokinetics Buy Rating: Strategic Developments and Market Opportunities Drive Optimism Despite FDA Delay
- Cytokinetics: Strong Financials and Promising Pipeline Drive Buy Rating
- Cytokinetics price target lowered to $80 from $86 at Citi